Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL488948 | 1.00 | PYGB (0.70) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL7150986 | 1.00 | PYGB (0.70) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL4388634 | 1.00 | PYGB (0.70) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL12510566 | 1.00 | PYGB (0.70) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL7150977 | 1.00 | PYGB (0.70) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL7149670 | 0.98 | PYGB (0.67) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL468706 | 0.98 | PYGB (0.67) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL31477900 | 0.88 | PYGB (0.64) | PYGBGAAAKR1B1CA12CA1 | |
| SCHEMBL4307948 | 0.86 | PYGB (0.62) | PYGBGAA | |
| SCHEMBL9302995 | 0.86 | CA1 (0.60) | PYGBGAACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120005043-A | Short peptide for inhibiting PRDX 1O-GlcNAc modification and application thereof | 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) | 2025-05-16 | — | — | CN | claimed |
| EP-4138856-A1 | A NANO-ENABLED VACCINATION APPROACH FOR CORONAVIRUS DISEASE (COVID-19) AND OTHER VIRAL DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-01 | — | — | EP | claimed |
| CN-110997917-A | Nucleic acid, composition containing nucleic acid, conjugate, preparation method and application | 苏州瑞博生物技术有限公司 | 2020-04-10 | — | — | CN | claimed |
| CN-110945130-A | Nucleic acid, composition containing nucleic acid, conjugate, preparation method and application | 苏州瑞博生物技术有限公司 | 2020-03-31 | — | — | CN | claimed |
| US-20050171194-A1 | Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions | YU RUEY J (US) | 2005-08-04 | — | — | US | claimed |
| WO-2005055947-A2 | ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS | YU RUEY J (US) | 2005-06-23 | — | — | WO | claimed |
| US-5539091-A | N-alkyl, n-acetylglycosylamines | STEPAN EUROPE (FR) | 1996-07-23 | — | — | US | claimed |
| US-20260062495-A1 | COMMERCIAL-SCALE RECOMBINANT PROTEIN PRODUCTION IN RAT HYBRIDOMA CELLS | TG THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| CN-121574953-A | Cell membrane-penetrating fusion peptide S517-pe and application thereof | 重庆医科大学 | 2026-02-27 | — | — | CN | disclosed |
| US-20250368741-A1 | FCRN ANTAGONIST MOLECULES AND METHODS OF USE THEREOF | argenx BV (BE) | 2025-12-04 | — | — | US | disclosed |
| CN-119064582-B | Application of RIPK 1O-GlcNAc glycosylation inhibitor in preparation of drug for enhancing sensitivity of renal cell carcinoma sunitinib | 南方医科大学南方医院 | 2025-05-27 | — | — | CN | disclosed |
| CN-119064582-B | Application of RIPK 1O-GlcNAc glycosylation inhibitor in preparation of drug for enhancing sensitivity of renal cell carcinoma sunitinib | 南方医科大学南方医院 | 2025-05-27 | — | — | CN | disclosed |
| CN-120005043-A | Short peptide for inhibiting PRDX 1O-GlcNAc modification and application thereof | 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) | 2025-05-16 | — | — | CN | disclosed |
| EP-0600359-B1 | Process for increasing the bleaching efficiency of an inorganic persalt or of hydrogen peroxide | AUSIMONT SPA (IT) | 1997-07-23 | — | — | EP | disclosed |
| US-5539091-A | N-alkyl, n-acetylglycosylamines | STEPAN EUROPE (FR) | 1996-07-23 | — | — | US | disclosed |
| EP-0606925-A2 | A method for derivatizing a 1-amino-1-deoxyoligosaccharide | Genzyme Corporation (US) | 1994-07-20 | — | — | EP | disclosed |
| US-5324828-A | Fluorescent compound | GENZYME CORPORATION (US) | 1994-06-28 | — | — | US | disclosed |
| EP-0299007-A4 | PREPARATION OF 1-AMINO-1-DEOXYOLIGOSACCHARIDES AND DERIVATIVES THEREOF. | GENZYME CORP (US) | 1990-03-08 | — | — | EP | disclosed |
| EP-0299007-A1 | PREPARATION OF 1-AMINO-1-DEOXYOLIGOSACCHARIDES AND DERIVATIVES THEREOF | GENZYME CORPORATION (US) | 1989-01-18 | — | — | EP | disclosed |
| WO-1988004323-A1 | PREPARATION OF 1-AMINO-1-DEOXYOLIGOSACCHARIDES AND DERIVATIVES THEREOF | GENZYME CORPORATION (US) | 1988-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368741-A1 | FCRN ANTAGONIST MOLECULES AND METHODS OF USE THEREOF | FCGR3B, FCGR2A, FCGRT | PYGB 3349/4885GAA 4273/4885AKR1B1 4327/4885 |
| US-20260062495-A1 | COMMERCIAL-SCALE RECOMBINANT PROTEIN PRODUCTION IN RAT HYBRIDOMA CELLS | MRPL21, YIPF5, ERN2 | PYGB 94/4885GAA 1093/4885AKR1B1 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.